ClinicalTrials.gg
CompletedNCT04171687Updated May 8, 2020

Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers

A Phase 1 interventional study of Clopidogrel 75mg and Tegoprazan 50 mg in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-08.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

This study aims to evaluate the influence of tegoprazan or RAPA113 on the pharmacodynamics/Pharmacokinetics of following co-administration of tegoprazan or RAPA113 and clopidogrel in healthy male volunteers.

Read the detailed description

Evaluation Criteria:

  • Primary outcome Pharmacodynamic assessments using P2Y12 assay
  • Secondary outcome Pharmacokinetics assessments on Cmax,ss, AUCτ,ss, tmax,ss, Cmin,ss , CLss/F of Clopidogrel
  • Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written
  • Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with (BMI) of ≥ 18.5 kg/m2 and ≤ 27.0 kg/m2 at the time of screening
  • Helicobacter pylori negative
  • Voluntarily decided to participate in the study and provided written informed consent before any screening procedure

Exclusion criteria

Exclusion Criteria:

  • Has a history of or currently has liver, kidney, nervous system, immune system, respiratory system, endocrine system, blood, tumor, cardiovascular system or psychiatric disease
  • Has a history of gastrointestinal diseases (such as Crohn's disease, ulcer, etc.) or surgery (except for simple appendectomy or hernia) that can affect the absorption of drugs
  • Has a genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • Has a clinically significant history of hemorrhage (e.g. Gastric ulcers, intracranial bleeding, haemophilia, gastrointestinal bleeding, urinary tract bleeding, vitreous hemorrhage, etc.)
  • P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range by 10% at screening
  • Considered ineligible to participate in the study based on screening test(by asking condition, vital sign, 12-lead , physical exam, laboratory test etc.) results :

    1. , PT and levels outside the upper/lower limit of normal range by 10%
    2. (GOT), and ALT (GPT) levels greater than 1.25x of the
    3. Blood total levels greater than 1.5x of the upper limit of normal range
    4. levels less than 12.0 g/dL
    5. (estimated Glomerular Filtration Rate) using MDRD (Modification of Diet in Renal Disaster) \< 60 mL/min/1.73 m2

      : eGFR (estimated glomerular filtration rate) (mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age]-0.203

    6. positive as a result of serum examination (B-type hepatitis test, test, test, syphilis test)
    7. Systolic blood pressure \< 90 mmHg or > 150 mmHg, diastolic blood pressure \< 50 mmHg or > 100 mmHg, or pulse rate \< 45 beats/minute or > 100 beats/minute when vital signs are measured in sitting position after resting for at least 5 minutes during screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Clopidogrel 75 mg

    Oral administration of clopidogrel 75 mg tablet once daily for 7 days

    Drug: Clopidogrel 75mg

  • Experimental
    Clopidogrel 75 mg + Tegoprazan 50 mg

    Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days

    Drug: Clopidogrel 75mg · Drug: Tegoprazan 50 mg

  • Experimental
    Clopidogrel 75 mg + RAPA113

    Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days

    Drug: Clopidogrel 75mg · Drug: RAPA113

Interventions

06

What researchers measure

Primary outcomes

  1. Change in P2Y12 Reaction Unit (PRU) from baseline

    Pharmacodynamics blood sampling to measure PRU using VerifyNow® system

    Time frame: Pre-dose(0h) on days 1, 3, 5, 7 and 8 in each period

07

Study locations

1 site
  • Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Feb 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2019
First posted
Nov 21, 2019
StartActual
Oct 21, 2019
Primary completionActual
Feb 7, 2020
CompletionActual
Apr 9, 2020
Last update
May 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04171687
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Oct 21, 2019
Primary completion
Feb 7, 2020
Completion
Apr 9, 2020
Last update
May 8, 2020

Study contacts

Min Soo Park
principal investigator · Severance Hospital, Dept of Clinical Pharmacology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clopidogrel · Tegoprazan

Start the discussion